Covered recipient · General Payments record
ARTHUR R MABAQUIAO
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$22,019.78
247 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $7,940.00 | 2 |
| Food and Beverage | $4,541.79 | 234 |
| Honoraria | $4,490.00 | 4 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,100.00 | 2 |
| Travel and Lodging | $798.86 | 1 |
| Education | $149.13 | 4 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | $8,103.33 | 16 |
| Horizon Therapeutics plc | $5,054.51 | 41 |
| Mallinckrodt Hospital Products Inc. | $3,317.92 | 13 |
| UCB, Inc. | $2,407.69 | 14 |
| Amgen Inc. | $762.77 | 36 |
| GlaxoSmithKline, LLC. | $295.88 | 15 |
| Janssen Biotech, Inc. | $266.96 | 20 |
| PFIZER INC. | $264.21 | 10 |
| Novartis Pharmaceuticals Corporation | $259.85 | 13 |
| AbbVie Inc. | $254.42 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $214.19 | 10 |
| Genentech USA, Inc. | $211.17 | 10 |
| Lilly USA, LLC | $83.97 | 4 |
| Alexion Pharmaceuticals, Inc. | $68.53 | 4 |
| Takeda Pharmaceuticals U.S.A., Inc. | $68.41 | 3 |
| E.R. Squibb & Sons, L.L.C. | $61.60 | 3 |
| Bayer HealthCare Pharmaceuticals Inc. | $49.29 | 3 |
| FIDIA PHARMA USA INC. | $45.37 | 2 |
| Eisai Inc. | $43.70 | 3 |
| Janssen Scientific Affairs, LLC | $36.71 | 3 |
| CSL Behring | $34.92 | 2 |
| Allergan, Inc. | $28.24 | 2 |
| Avion Pharmaceuticals | $25.28 | 2 |
| GENZYME CORPORATION | $20.22 | 1 |
| Gilead Sciences, Inc. | $15.14 | 1 |
| Arbor Pharmaceuticals, Inc. | $13.66 | 1 |
| MEDEXUS PHARMA, INC. | $11.84 | 1 |
Page 2 of 5; records 51–100 of 247 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ARTHUR R MABAQUIAO
NPI 1730271933 · CMS profile ID 351444
Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology
SAN DIEGO, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 5; records 51–100 of 247 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1730271933?year=2020&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ARTHUR R MABAQUIAO, NPI 1730271933, CMS profile ID 351444. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 247 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1730271933?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). ARTHUR R MABAQUIAO, NPI 1730271933, CMS profile ID 351444. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 247 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1730271933?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- ARTHUR R MABAQUIAO, NPI 1730271933, CMS profile ID 351444, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 247 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1730271933?year=2020&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
247 matching records · $22,019.78 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 247.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Horizon Therapeutics plc | $8.65 | 10/22/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721418777 | CMS |
| Horizon Therapeutics plc | $4.27 | 10/22/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721418779 | CMS |
| Amgen Inc. | $18.39 | 10/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 740918469 | CMS |
| Amgen Inc. | $22.34 | 10/19/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 740918465 | CMS |
| GlaxoSmithKline, LLC. | $13.86 | 10/16/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738513293 | CMS |
| GENZYME CORPORATION | $20.22 | 10/15/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 744151251 | CMS |
| AbbVie Inc. | $17.78 | 10/14/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 722009753 | CMS |
| Amgen Inc. | $124.26 | 10/14/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741369137 | CMS |
| FIDIA PHARMA USA INC. | $24.53 | 10/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 748296455 | CMS |
| Horizon Therapeutics plc | $2.24 | 10/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721418775 | CMS |
| UCB, Inc. | $15.16 | 10/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 746089111 | CMS |
| Actelion Pharmaceuticals US, Inc. | $10.98 | 10/12/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719034797 | CMS |
| Janssen Biotech, Inc. | $23.18 | 10/08/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719034879 | CMS |
| Janssen Biotech, Inc. | $21.00 | 10/07/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719034875 | CMS |
| Amgen Inc. | $22.16 | 10/06/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 740918455 | CMS |
| Novartis Pharmaceuticals Corporation | $19.42 | 10/05/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 725998393 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $27.82 | 10/02/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747259017 | CMS |
| Amgen Inc. | $30.18 | 10/01/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 740918485 | CMS |
| CSL Behring | $13.07 | 10/01/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 728951293 | CMS |
| AbbVie Inc. | $15.11 | 09/29/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 722009749 | CMS |
| Horizon Therapeutics plc | $19.37 | 09/26/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721418773 | CMS |
| GlaxoSmithKline, LLC. | $43.75 | 09/25/2020 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738513539 | CMS |
| GlaxoSmithKline, LLC. | $13.75 | 09/25/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738823241 | CMS |
| Eisai Inc. | $14.33 | 09/23/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751229399 | CMS |
| Horizon Therapeutics plc | $17.73 | 09/23/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721418771 | CMS |
| Amgen Inc. | $18.64 | 09/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 741369133 | CMS |
| Novartis Pharmaceuticals Corporation | $17.12 | 09/18/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 725998385 | CMS |
| PFIZER INC. | $20.99 | 09/18/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743366063 | CMS |
| AbbVie Inc. | $21.63 | 09/17/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 722009745 | CMS |
| Amgen Inc. | $16.19 | 09/15/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 740918453 | CMS |
| Novartis Pharmaceuticals Corporation | $19.92 | 09/15/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 725998389 | CMS |
| Mallinckrodt Hospital Products Inc. | $34.96 | 09/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751708347 | CMS |
| Janssen Scientific Affairs, LLC | $13.03 | 09/09/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719034893 | CMS |
| Actelion Pharmaceuticals US, Inc. | $17.34 | 09/08/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719034793 | CMS |
| AbbVie Inc. | $19.96 | 09/03/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 722009743 | CMS |
| Amgen Inc. | $17.95 | 09/03/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 740918449 | CMS |
| Amgen Inc. | $8.71 | 09/03/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 740918481 | CMS |
| Janssen Biotech, Inc. | $7.41 | 09/01/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719034861 | CMS |
| Janssen Biotech, Inc. | $0.93 | 09/01/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719034865 | CMS |
| Mallinckrodt Hospital Products Inc. | $27.06 | 09/01/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751708345 | CMS |
| Novartis Pharmaceuticals Corporation | $25.00 | 08/28/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 725998381 | CMS |
| Horizon Therapeutics plc | $7.76 | 08/27/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721418769 | CMS |
| PFIZER INC. | $17.58 | 08/26/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743364595 | CMS |
| AbbVie Inc. | $22.72 | 08/22/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 722009739 | CMS |
| Alexion Pharmaceuticals, Inc. | $17.89 | 08/20/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 726629195 | CMS |
| UCB, Inc. | $37.75 | 08/18/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 746091739 | CMS |
| Amgen Inc. | $8.60 | 08/17/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 740918507 | CMS |
| Amgen Inc. | $17.93 | 08/14/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 740918447 | CMS |
| Mallinckrodt Hospital Products Inc. | $27.16 | 08/14/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 751708343 | CMS |
| GlaxoSmithKline, LLC. | $34.46 | 08/13/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 738854023 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $287,193.16 | 52 |
| PY2024 | Principal investigator | $78,438.66 | 21 |
| PY2023 | Principal investigator | $100,092.49 | 50 |
| PY2022 | Principal investigator | $78,023.62 | 39 |
| PY2021 | Principal investigator | $191,358.52 | 46 |
| PY2020 | Principal investigator | $201,814.43 | 53 |
| PY2019 | Principal investigator | $452,493.85 | 84 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
52 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $200.00 | 12/19/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CEN | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223290024 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,608.70 | 12/17/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CEN | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223289778 |
| Principal investigator 1 | Mesoblast, Inc. | $8,315.00 | 12/05/2025 | Non-covered Recipient Entity Advanced Clinical Research Center | MSB-DR004 | No dispute reported | 06/30/2026 | 1228251880 |
| Principal investigator 1 | ABBVIE INC. | $1,300.99 | 12/04/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CENTER | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 1202528884 |
| Principal investigator 1 | ABBVIE INC. | $6,322.95 | 12/04/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CENTER | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202528886 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,103.05 | 12/01/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CEN | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223288867 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,936.25 | 11/19/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CEN | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223288493 |
| Principal investigator 1 | ABBVIE INC. | $155.25 | 11/18/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CENTER | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202524527 |
| Principal investigator 1 | ABBVIE INC. | $750.60 | 11/18/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CENTER | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202524539 |
| Principal investigator 1 | Mesoblast, Inc. | $22,432.00 | 11/14/2025 | Non-covered Recipient Entity Advanced Clinical Research Center | MSB-DR004 | No dispute reported | 06/30/2026 | 1228251878 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $438.00 | 11/12/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CEN | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223288243 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $500.00 | 11/12/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CEN | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223288249 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $134.00 | 11/12/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CEN | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223288251 |
| Principal investigator 1 | ABBVIE INC. | $8,590.20 | 11/05/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CENTER | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202522035 |
| Principal investigator 1 | ABBVIE INC. | $186.30 | 10/16/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CENTER | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202517185 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,517.75 | 10/15/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CEN | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223286951 |
| Principal investigator 1 | ABBVIE INC. | $14,024.00 | 10/09/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CENTER | A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis | No dispute reported | 06/30/2026 | 1202514729 |
| Principal investigator 1 | Mesoblast, Inc. | $13,284.00 | 10/03/2025 | Non-covered Recipient Entity Advanced Clinical Research Center | MSB-DR004 | No dispute reported | 06/30/2026 | 1228251868 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,551.50 | 10/03/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CEN | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223286303 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,737.80 | 09/24/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CENTER LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223285840 |
| Principal investigator 1 | Mesoblast, Inc. | $26,864.00 | 09/12/2025 | Non-covered Recipient Entity Advanced Clinical Research Center | MSB-DR004 | No dispute reported | 06/30/2026 | 1228251960 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $292.00 | 09/10/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CENTER LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223285255 |
| Principal investigator 1 | ABBVIE INC. | $1,584.39 | 09/04/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CENTER | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 1202509190 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,551.50 | 08/27/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CENTER LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223284621 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,153.25 | 08/27/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CENTER LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223284623 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,000.00 | 08/15/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CENTER L LC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175426127 |
| Principal investigator 1 | ABBVIE INC. | $1,398.60 | 08/14/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CENTER | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202504873 |
| Principal investigator 1 | Mesoblast, Inc. | $15,404.00 | 08/08/2025 | Non-covered Recipient Entity Advanced Clinical Research Center | MSB-DR004 | No dispute reported | 06/30/2026 | 1228251866 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,187.05 | 08/01/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CENTER LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223283443 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,500.00 | 07/24/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CENTER L LC | ?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? | No dispute reported | 06/30/2026 | 1175426133 |
| Principal investigator 1 | ABBVIE INC. | $6,375.00 | 07/10/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CENTER | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202497906 |
| Principal investigator 1 | Mesoblast, Inc. | $7,017.00 | 07/03/2025 | Non-covered Recipient Entity Advanced Clinical Research Center | MSB-DR004 | No dispute reported | 06/30/2026 | 1228251872 |
| Principal investigator 1 | ABBVIE INC. | $1,300.99 | 07/02/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CENTER | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 1202495147 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000.00 | 06/20/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CENTER LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223281704 |
| Principal investigator 1 | Mesoblast, Inc. | $4,083.00 | 06/06/2025 | Non-covered Recipient Entity Advanced Clinical Research Center | MSB-DR004 | No dispute reported | 06/30/2026 | 1228251876 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,500.00 | 05/28/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CENTER LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223280474 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $5,500.00 | 05/16/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CENTER LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223279912 |
| Principal investigator 1 | Mesoblast, Inc. | $250.00 | 05/09/2025 | Non-covered Recipient Entity Advanced Clinical Research Center | MSB-DR004 | No dispute reported | 06/30/2026 | 1228251874 |
| Principal investigator 1 | ABBVIE INC. | $4,220.10 | 05/07/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CENTER | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202483445 |
| Principal investigator 1 | Mesoblast, Inc. | $1,952.00 | 04/18/2025 | Non-covered Recipient Entity Advanced Clinical Research Center | MSB-DR004 | No dispute reported | 06/30/2026 | 1228251870 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,000.00 | 04/16/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CENTER LLC | A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) | No dispute reported | 06/30/2026 | 1223278126 |
| Principal investigator 1 | Eli Lilly and Company | $6,532.00 | 04/11/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CENTER LLC | A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS | No dispute reported | 06/30/2026 | 1187873553 |
| Principal investigator 1 | ABBVIE INC. | $1,300.99 | 04/03/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CENTER | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 1202469331 |
| Principal investigator 1 | ABBVIE INC. | $2,600.00 | 04/01/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CENTER | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 1202467760 |
| Principal investigator 1 | ABBVIE INC. | $585.30 | 03/27/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CENTER | M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 1202466937 |
| Principal investigator 1 | ABBVIE INC. | $355.80 | 03/27/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CENTER | M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 1202466988 |
| Principal investigator 1 | ABBVIE INC. | $14,000.00 | 03/07/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CENTER | M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202461561 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,100.00 | 02/27/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CENTER TRIWEST RESEARCH ASSOCIATES | A Randomized, Two-arm, Placebo-controlled, Participant and Investigator-blinded Study Investigating the Efficacy, Safety and Tolerability of DFV890 in Patients With Symptomatic Knee Osteoarthritis | No dispute reported | 06/30/2026 | 1190312633 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $36,895.53 | 02/26/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CENTER | A Multicenter,Randomized,Double blind,Placebo controlled,Phase III Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Systemic Sclerosis | No dispute reported | 06/30/2026 | 1185551929 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $243.01 | 02/10/2025 | Non-covered Recipient Entity TRIWEST RESEARCH ASSOCIATES | A Randomized, Two-arm, Placebo-controlled, Participant and Investigator-blinded Study Investigating the Efficacy, Safety and Tolerability of DFV890 in Patients With Symptomatic Knee Osteoarthritis | No dispute reported | 06/30/2026 | 1190303867 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $58.32 | 01/15/2025 | Non-covered Recipient Entity TRIWEST RESERACH ASSOCIATES | A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy | No dispute reported | 06/30/2026 | 1190303811 |
| Principal investigator 1 | ABBVIE INC. | $1,300.99 | 01/02/2025 | Non-covered Recipient Entity ADVANCED CLINICAL RESEARCH CENTER | M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 1202434184 |